Preliminary results of Preserflo Microshunt versus Preserflo Microshunt and Ologen implantation.

Vastardis IraklisSofia FiliGeorgios PerdikakisKalliopi KontopoulouMiltos BalidisZisis GatzioufasMarkus Kohlhaas

Published in: Eye and vision (London, England) (2021)

Both groups showed equal results in terms of cumulative and mean IOP reduction, medication reduction as well as in absolute and qualified success rates. No significant difference was found in any parameters tested between Preserflo Microshunt with MMC 0.2 mg/ml and with or without OCM implantation at 6 months. Long-term follow-up is required to further evaluate this data.

Keyphrases

healthcare
electronic health record
big data
emergency department
adverse drug
data analysis